Renal Safety of Intravitreal Ranibizumab and the Effects of SGLT2 Inhibition in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial.

Lucentis (ranibizumab) - Roche, Novartis

http://www.ncbi.nlm.nih.gov/pubmed/42717542

Kenichi Sakurai; Koutaro Yokote; Masaya Koshizaka; Ryoichi Ishibashi; Takayuki Baba; Tomoaki Tatsumi; Toshiki Sakai; Yoko Takatsuna; Yoshiro Maezawa

Sep 11, 2026